Targeting interferon-alpha to dendritic cells enhances a CD8 + T cell response to a human CD40-targeted cancer vaccine

2017/07/23 by John P. Graham, John Graham, Pierre Authie +5 · 7 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Adjuvant #Antigen #Antigen presentation #Antigen-presenting cell #Biochemistry #Biology #CD40 #CD8 #Cancer research #Cross-presentation #Cytotoxic T cell #Dendritic cell #Immune system #Immunology #Immunotherapy #Immunotherapy and Immune Responses #In vitro #T cell #T-cell and B-cell Immunology #vaccines and immunoinformatics approaches

paper · doi:10.1016/j.vaccine.2017.07.032

openalex publication_date 2017/07/23 · openalex created_date 2017/07/31 · openalex updated_date 2026/08/01

Cited by

• A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. [europepmc]
• Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. [europepmc]
• Role of Type I Interferons on Filovirus Pathogenesis. [europepmc]
• Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. [europepmc]
• Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. [europepmc]
• Type I and II Interferons in the Anti-Tumor Immune Response. [europepmc]
• Recent Advances and Challenges in Cancer Immunotherapy. [europepmc]